Kit Products (Ex-US)
Our ultra-sensitive OncoBEAM™ and Plasma-SeqSensei Kit products are developed to provide reliable molecular information for timely and non-invasive treatment selection, molecular monitoring and enhanced prediction of resistance to therapy.
Depending on the clinical issue, clinicians can choose between different available kits based on the highly sensitive technologies BEAMing (digital PCR) or SafeSEQ (NGS), which can be run on-site in clinically validated laboratories. For analysis only a simple blood draw is needed.
OncoBEAM™ Kits (EX-US)
Our digital PCR-based OncoBEAM™ Kits can be used to identify and select patients, which are suitable for cancer-specific therapy. Different Kits for Lung cancer and Coloractal cancer are available.
Plasma-SeqSensei™ Kits (EX-US)
Plasma-SeqSensei Kits are SafeSeq NGS liquid biopsy solutions designed to detect genomic alterations and characterized hotspot regions responsible for clinically relevant targets.
Cancer type specific kits
The highly sensitive detection capacity of our Plasma-SeqSensei™ RUO Kits will allow for identification of clinically-relevant mutations for breast cancer, colorectal cancer, NSCLC, AML and head and neck cancer.Learn More
The OncoBEAM™ EGFR kit v2 enables the detection of EGFR mutations which play an essential role for therapy selection in non-small cell lung cancer (NSCLC).Learn More
Sysmex Inostics‘ highly sensitive OncoBEAM™ RAS CRC & BRAF kits use the non-invasive liquid biopsy mutation detection technology to analyze the cell-free circulating Tumor DNA which enables to select CRC patients eligible for anti-EGFR therapy.Learn More